Lactate Metabolism After an Endotoxin Challenge in Healthy Humans

July 19, 2012 updated by: Luc Tappy, MD, University of Lausanne

Effects of an Acute Administration of Bacterial Endotoxin on Whole Body and Regional Lactate Metabolism in Healthy Male Volunteers

Sepsis is characterized by hyperlactatemia, the severity of which is proportionate with sepsis severity. The pathophysiological mechanisms (increased lactate production vs decreased lactate utilization; tissues involved in sepsis-induced lactate production) remain largely unknown.

In this study, the investigators will assess whole body and regional metabolism in healthy young male subjects on two occasions, once after administration of an intravenous bacterial endotoxin challenge, and once without intervention.

In one group of subjects, whole body lactate metabolism will be measured over 10 hours after the endotoxin challenge

  • Energy expenditure and net substrate oxidation rates (indirect calorimetry)
  • Lactate kinetics (measured by means of a continuous, exogenous sodium lactate infusion)
  • Glucose kinetics (measured with 6,6 d2 glucose)
  • Hemodynamic parameters and body temperature
  • Blood clinical chemistry In one group of subjects, whole body lactate metabolism will be measured over 10 hours after the endotoxin challenge
  • Energy expenditure and net substrate oxidation rates (indirect calorimetry)
  • Lactate kinetics (measured by means of a continuous, exogenous sodium lactate infusion)
  • Glucose kinetics (measured with 6,6 d2 glucose)
  • Hemodynamic parameters and body temperature
  • Blood clinical chemistry

In a second group of subjects, regional muscle lactate metabolism will be measured over 10 hours after the endotoxin challenge by means of muscle microdialysis

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
    • Vaud
      • Lausanne, Vaud, Switzerland, CH-1011
        • Centre Hospitalier Universitaire Vaudois

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • gender male
  • body mass index (BMI) < 25 kg/m2
  • absence of known disease

Exclusion Criteria:

  • any known pathology
  • abnormal cardio-pulmonary and hemodynamic status
  • electrocardiographic alterations
  • history of allergy
  • current medications
  • drug abuse
  • consumption of more than 20g/day alcohol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: study 1a
whole body lactate production after bacterial endotoxin challenge
Other: bacterial endotoxin challenge
iv administration of 2ng/kg bacterial endotoxin
No Intervention: study 1b
basal whole body lactate production
Experimental: study 2a
muscle lactate concentration after bacterial endotoxin challenge
Other: bacterial endotoxin challenge
iv administration of 2ng/kg bacterial endotoxin
No Intervention: study 2b
basal muscle lactate concentrations

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Whole body lactate production
Time Frame: single bacterial endotoxin administration; measurements over 6.5 hours following administration

Whole body lactate clearance will be measured by measuring the increase in blood lactate at steady state during a conrtinuous exogenous sodium lactate infusion.

Lactate production will be calculated as the product of lactate clearance times per-infusion blood lactate concentration
single bacterial endotoxin administration; measurements over 6.5 hours following administration
skeletal muscle lactate concentration
Time Frame: single bacterial endotoxin administration; measurements over 6.5 hours following administration
interstitial muscle measured by means of in vivo microdialysis ; calculation of muscle-blood lactate gradient
single bacterial endotoxin administration; measurements over 6.5 hours following administration

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
whole body energy expenditure
Time Frame: single bacterial endotoxin administration; measurements over 6.5 hours following administration
open circuit indirect calorimetry (hood)
single bacterial endotoxin administration; measurements over 6.5 hours following administration
body temperature
Time Frame: single bacterial endotoxin administration; measurements over 6.5 hours following administration
single bacterial endotoxin administration; measurements over 6.5 hours following administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Lausanne

Collaborators

Centre Hospitalier Universitaire Vaudois

Investigators

  • Principal Investigator: René Chiolero, MD, Centre Hospitalier Universitaire Vaudois

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2002

Primary Completion (Actual)

March 1, 2004

Study Completion (Actual)

December 1, 2004

Study Registration Dates

First Submitted

July 17, 2012

First Submitted That Met QC Criteria

July 19, 2012

First Posted (Estimate)

July 24, 2012

Study Record Updates

Last Update Posted (Estimate)

July 24, 2012

Last Update Submitted That Met QC Criteria

July 19, 2012

Last Verified

July 1, 2012

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • Lsne-128/01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

Clinical Trials on bacterial endotoxin challenge

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe